Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

Activating BRAF(V600E) (Val600Glu) mutations are found in about 1-2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in these patients. Dabrafenib is an oral selective inhibitor of BRAF kinase. We did a trial to assess the clinical activity of dabrafenib in patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2016-05, Vol.17 (5), p.642-650
Hauptverfasser:	Planchard, David, Kim, Tae Min, Mazieres, Julien, Quoix, Elisabeth, Riely, Gregory, Barlesi, Fabrice, Souquet, Pierre-Jean, Smit, Egbert F, Groen, Harry J M, Kelly, Ronan J, Cho, B C, Socinski, Mark A, Pandite, Lini, Nase, Christine, Ma, Bo, D'Amelio, Jr, Anthony, Mookerjee, Bijoyesh, Curtis, Jr, C Martin, Johnson, Bruce E
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Aged Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Disease-Free Survival Dose-Response Relationship, Drug Female Humans Imidazoles - administration & dosage Imidazoles - adverse effects Male Middle Aged Mutation Neoplasm Staging Oximes - administration & dosage Oximes - adverse effects Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Proto-Oncogene Proteins B-raf - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!